Company Announcement no. 18/2008
To: OMX Nordic Exchange Copenhagen Hørsholm, Denmark, April 17, 2008
Major shareholder announcements
Hørsholm, Denmark, 17 April 2008; LifeCycle Pharma A/S (OMX: LCP) today
announced that LCP has received a notice that Novo A/S has increased their
holdings of LCP shares from 4,096,416 to 11,628,269 shares, corresponding to
20.73 % of the shares in LCP.
About LifeCycle Pharma A/S (“LCP”)
LCP is an emerging specialty pharmaceutical company that, through innovative
technologies, is able to rapidly develop a portfolio of differentiated products
to meet the unique needs of key therapeutic markets and patient populations.
This includes products for immunosuppression, specifically organ
transplantation, and to combat certain cardiovascular diseases. By using its
unique and patented delivery technology, MeltDose®, LCP is able to develop
drugs with enhanced absorption and thereby increased bioavailability. LCP has a
cholesterol lowering product, FenoglideTM, currently on the U.S. market and a
diversified near- and medium-term pipeline, including five product candidates
in clinical trials and three in preclinical stages of development. LCP is
listed on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX:
LCP).
For further information please contact LifeCycle Pharma A/S:
Hans Christian Teisen
Executive Vice President & CFO
+45 20 30 69 85;
E-mail: hct@lcpharma.com
